Comprehensive Review of Sativex for MS Spasticity: How It Works and What the Trials Show
A detailed drug review found Sativex significantly reduced MS spasticity in patients who responded to an initial trial period, with dizziness and fatigue as the most common early side effects.
Quick Facts
What This Study Found
In the largest multinational clinical trial using the approved treatment protocol, Sativex significantly reduced spasticity severity compared to placebo after 12 weeks in patients who had demonstrated initial response during a 4-week trial period. A significantly greater proportion of Sativex-treated patients achieved a 30% or greater reduction in spasticity (considered clinically relevant).
The approved protocol includes an important initial trial of therapy: only patients who demonstrate clinically significant improvement during the first 4 weeks continue treatment. This enrichment design ensures the drug is used in patients most likely to benefit.
Real-world effectiveness data from the MOVE 2 study confirmed clinical trial findings. Side effects (primarily dizziness and fatigue) were most common in the first 4 weeks and typically resolved even with continued treatment.
Key Numbers
THC:CBD ratio approximately 1:1. Approved as add-on therapy for moderate to severe MS spasticity. Initial trial period: 4 weeks. Pivotal trial: 12 weeks double-blind. Significant 30% responder rate. Most common side effects: dizziness, fatigue (resolving within days).
How They Did This
This is a comprehensive drug review covering the pharmacology, clinical efficacy, and tolerability of Sativex (THC/CBD oromucosal spray). It synthesizes data from Phase III clinical trials, the MOVE 2 real-world study, and pharmacological characterization.
Why This Research Matters
This review provides the most complete picture available of Sativex as a treatment for MS spasticity, covering everything from its mechanism of action to its real-world effectiveness. The enrichment design (initial trial period) is a model for how cannabinoid medicines can be used to identify and treat responsive patients.
The Bigger Picture
Sativex represents the most extensively studied cannabinoid medicine for a specific indication. Its approval pathway, including the initial trial period, has influenced how other cannabinoid medicines are developed and prescribed. It demonstrates that cannabis-derived medicines can meet pharmaceutical regulatory standards.
What This Study Doesn't Tell Us
The enrichment design (4-week trial period) means efficacy data applies only to responders, not all MS spasticity patients. Long-term efficacy and safety data beyond clinical trial durations were limited. The review was published in a pharmaceutical journal and follows a standard drug review format that may not critically evaluate all limitations.
Questions This Raises
- ?What proportion of MS spasticity patients respond during the initial trial period?
- ?Does long-term tolerance develop?
- ?Would Sativex be effective for spasticity from causes other than MS?
Trust & Context
- Key Stat:
- Significantly more Sativex patients achieved 30% spasticity reduction vs. placebo
- Evidence Grade:
- This review covers Phase III trial data and real-world effectiveness studies, representing strong evidence for the approved indication.
- Study Age:
- Published in 2014. Sativex has since been approved in additional countries and accumulated more long-term safety data.
- Original Title:
- Delta-9-tetrahydrocannabinol/cannabidiol (Sativex®): a review of its use in patients with moderate to severe spasticity due to multiple sclerosis.
- Published In:
- Drugs, 74(5), 563-78 (2014)
- Authors:
- Syed, Yahiya Y, McKeage, Kate, Scott, Lesley J
- Database ID:
- RTHC-00874
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
What is the initial trial period?
Sativex is approved with a requirement for a 4-week initial trial. Only patients who show meaningful improvement during this period should continue treatment. This ensures the drug is used in patients who actually respond to it, improving overall treatment outcomes.
How does Sativex work?
THC in Sativex acts as a partial agonist at cannabinoid CB1 and CB2 receptors, modulating excitatory (glutamate) and inhibitory (GABA) neurotransmitters. CBD may contribute additional effects. Together, they reduce the excessive muscle tone that causes spasticity in MS.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-00874APA
Syed, Yahiya Y; McKeage, Kate; Scott, Lesley J. (2014). Delta-9-tetrahydrocannabinol/cannabidiol (Sativex®): a review of its use in patients with moderate to severe spasticity due to multiple sclerosis.. Drugs, 74(5), 563-78. https://doi.org/10.1007/s40265-014-0197-5
MLA
Syed, Yahiya Y, et al. "Delta-9-tetrahydrocannabinol/cannabidiol (Sativex®): a review of its use in patients with moderate to severe spasticity due to multiple sclerosis.." Drugs, 2014. https://doi.org/10.1007/s40265-014-0197-5
RethinkTHC
RethinkTHC Research Database. "Delta-9-tetrahydrocannabinol/cannabidiol (Sativex®): a revie..." RTHC-00874. Retrieved from https://rethinkthc.com/research/syed-2014-delta9tetrahydrocannabinolcannabidiol-sativex-a-review
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.